ARS Pharmaceuticals, Inc Asset Resilience Ratio
ARS Pharmaceuticals, Inc asset resilience ratio. ARS Pharmaceuticals, Inc (SPRY) has an Asset Resilience Ratio of 62.16% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SPRY defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ARS Pharmaceuticals, Inc (2021–2025)
Asset resilience ratio of ARS Pharmaceuticals, Inc from 2021 to 2025. This chart shows how ARS Pharmaceuticals, Inc's Asset Resilience Ratio has changed over time. Read ARS Pharmaceuticals, Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ARS Pharmaceuticals, Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SPRY total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $203.67 Million | 62.16% |
| Total Liquid Assets | $203.67 Million | 62.16% |
Asset Resilience Insights
- Very High Liquidity: ARS Pharmaceuticals, Inc maintains exceptional liquid asset reserves at 62.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ARS Pharmaceuticals, Inc Industry Peers by Asset Resilience Ratio
Compare ARS Pharmaceuticals, Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
ARS Pharmaceuticals, Inc Asset Resilience Ratio by Year (2021–2025)
ARS Pharmaceuticals, Inc asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for ARS Pharmaceuticals, Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 62.16% | $203.67 Million | $327.65 Million | -12.79pp |
| 2024-12-31 | 74.95% | $263.20 Million | $351.15 Million | +7.46pp |
| 2023-12-31 | 67.49% | $157.39 Million | $233.19 Million | +44.80pp |
| 2022-12-31 | 22.69% | $63.86 Million | $281.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $61.45 Million | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more